文献速递心脑血管急症重症综合管理与镇静镇痛

基于蛋白质组学的多标志物组合可提高神经丝轻链对心脏骤停后神经功能恢复的预测

Prediction of Neurological Recovery After Cardiac Arrest Using Neurofilament Light Chain is Improved by a Proteomics-Based Multimarker Panel.
PubMed 文献 · Neurocrit Care · 2021-08-03
一句话结论心脏骤停后48小时血浆NfL加入现有多标志物模型,预测出院和6个月神经功能不良的AUC分别达89.7%和93.7%,优于任一模型单独使用。

该研究在70例心脏骤停患者中,于复苏后48小时采血用单分子检测法测血浆NfL,以出院时和6个月CPC 1-2 vs 3-5二分类为终点。出院时30%患者预后良好。NfL随CPC分级升高而升高(16.5 pg/ml至641 pg/ml,p<0.001)。将NfL加入既有模型显著改善预测(Wald检验p<0.001),NfL联合多标志物模型的ROC曲线下面积在出院时89.7%(95%CI 81.7-97.7)、6个月93.7%(88.2-99.2),显著高于各模型单独使用。样本量较小,结论需进一步验证。

要点

  • 心脏骤停后48小时血浆NfL水平随CPC分级升高而升高(CPC 1为16.5 pg/ml,CPC 5为641 pg/ml,p<0.001),可作为轴索损伤的单一预测标志物。
  • NfL加入既有模型后预测能力显著改善(Wald检验p<0.001),提示多标志物联合策略优于单用NfL。
  • NfL联合多标志物模型预测出院时不良神经功能(CPC 3-5)的AUC为89.7%(95%CI 81.7-97.7),预测6个月不良预后的AUC为93.7%(95%CI 88.2-99.2)。
  • 联合模型AUC显著高于NfL单独模型和既有模型单独使用,但本研究样本仅70例,结论需外部队列验证。
  • 血浆NfL检测采用单分子检测法,采血时间点为心脏骤停后48小时,该时间窗和检测方法在临床推广前需标准化。

适用人群与场景

  • 心脏骤停后入住ICU并存活至48小时的患者,研究纳入70例,出院时21例(30%)为CPC 1-2,49例(70%)为CPC 3-5。

诊断标准与关键阈值

  • 神经功能结局采用脑功能分级(CPC)量表,出院时和6个月时记录,二分类为CPC 1-2(良好)vs CPC 3-5(不良)。
  • 血浆NfL于心脏骤停后48小时采血,用单分子检测法测定。
  • 预测性能用ROC曲线下面积评估,原文未给出临床决策的阈值。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型为单中心回顾性分析(原文未明确说明研究设计类型,仅描述为纳入70例患者的分析),无对照组,评估NfL单独及联合既有模型的预测价值。
  • 主要终点为出院时和6个月CPC 1-2 vs 3-5的预测AUC:NfL联合多标志物模型出院时AUC 89.7%(95%CI 81.7-97.7),6个月AUC 93.7%(95%CI 88.2-99.2),显著高于各模型单独使用。
  • NfL水平从CPC 1的16.5 pg/ml升至CPC 5的641 pg/ml(p<0.001)。
  • NfL加入既有模型后预测能力显著改善(Wald检验p<0.001)。

证据类型、等级与局限

  • 证据类型为单中心小样本(70例)观察性研究,原文未给出证据等级或推荐强度。
  • 局限:样本量相对较小,原文结论中明确提及;原文未说明是否回顾性、是否盲法评估结局。

对床旁实践的改变

  • 该研究提示心脏骤停后48小时血浆NfL联合多标志物模型可能提高神经功能预后预测准确性,但样本量小,尚不能作为床旁决策的唯一依据。
  • 适用人群为心脏骤停后存活至48小时的患者,不适用于未存活至48小时或未在48小时采血者。
  • 常见陷阱:NfL单用预测价值有限,需联合其他血浆和临床标志物;ROC阈值未在原文中给出,不能直接用于临床分类决策。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Continuous advances in resuscitation care have increased survival, but the rate of favorable neurological outcome remains low. We have shown the usefulness of proteomics in identifying novel biomarkers to predict neurological outcome. Neurofilament light chain (NfL), a marker of axonal damage, has since emerged as a promising single marker. The aim of this study was to assess the predictive value of NfL in comparison with and in addition to our established model.

METHODS: NfL was measured in plasma samples drawn at 48 h after cardiac arrest using single-molecule assays. Neurological function was recorded on the cerebral performance category (CPC) scale at discharge from the intensive care unit and after 6 months. The ability to predict a dichotomized outcome (CPC 1-2 vs. 3-5) was assessed with receiver operating characteristic (ROC) curves.

RESULTS: Seventy patients were included in this analysis, of whom 21 (30%) showed a favorable outcome (CPC 1-2), compared with 49 (70%) with an unfavorable outcome (CPC 3-5) at discharge. NfL increased from CPC 1 to 5 (16.5 pg/ml to 641 pg/ml, p < 0.001). The addition of NfL to the existing model improved it significantly (Wald test, p < 0.001), and the combination of NfL with a multimarker model showed high areas under the ROC curve (89.7% [95% confidence interval 81.7-97.7] at discharge and 93.7% [88.2-99.2] at 6 months) that were significantly greater than each model alone.

CONCLUSIONS: The combination of NfL with other plasma and clinical markers is superior to that of either model alone and achieves high areas under the ROC curve in this relatively small sample.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Wurm R, Arfsten H, Muqaku B, et al. Prediction of Neurological Recovery After Cardiac Arrest Using Neurofilament Light Chain is Improved by a Proteomics-Based Multimarker Panel. Neurocrit Care. 2021. PMID: 34342833. doi:10.1007/s12028-021-01321-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。